Frelii Expands Executive Team with Industry Veterans

“Frelii recently launched to the market and a positive result of that effort was signing our first revenue-generating customer in the Health & Wellness space. All the positive work the Frelii team has generated over the past months to launch the company, introduce our technology and products to our target markets, attract prospective customers, investors and ideal strategic partners will generate strong and sustainable growth opportunities for our company,” said Ian Jenkins, CEO of Frelii. “To optimize and support this high-growth stage, we’ve added new members to our leadership team for powerful and deep expertise across all functional areas of the organization. With Jayson Uffens, we already have one of the industry’s finest CTOs in charge of our unique technology. These new additions complete our executive team, enabling us to meet all of our strategic objectives. In our complex and rapidly evolving market, it is imperative that we have innovative, strong leadership to strengthen and optimize our operations, finance and strategic revenue generating opportunities. Frelii is bringing to market unique and new technologies that are designed to transform how human health is managed with artificial intelligence, DNA sequencing and whole genome analysis. Together, our leadership team will help guide Frelii’s path and fuel its success.”

As COO of Frelii, Norris will leverage her decades of experience as a business growth strategist, operations build-out, team development, channel programs, SOPs and compliance. She’ll handle a dual role as head of marketing and brand. She provides the leadership, management and vision to ensure the company emerges effectively into the right industries, verticals and with optimal partners, to effectively grow the organization. Norris will also serve as lead negotiator on new business and strategic partnership deals, to ensure balance between technology, deliverables, finance and operations.

Uppal joins Frelii as its Chief Administrative Officer. He has decades of experience as CFO for various insurance companies as well as extensive experience in strategic financial planning, mergers and acquisitions, contract negotiations, and support of public registration companies. He will be responsible for providing input on funding, finance, securities management, budgeting, strategic relationships and regulatory reporting. His extensive experience provides Frelii with the ability to growth the organization globally.

Aubin brings more than 20 years of senior finance experience in the Oil & Gas and Insurance industries to his role at Frelii as Executive Vice President of Finance. He has extensive experience in mergers and acquisitions, lending activities, risk management, and treasury. He will oversee financial related matters including the direction of financing strategies, analysis, forecasting, as well as supporting budget management and regulatory reporting

The management team also includes Jayson Uffens, Frelii’s Chief Technology Officer, who leads a team of expert software and SaaS engineers, and AI architects. Uffens brings nearly 20 years of experience and significant market success with several high visibility companies, including GrubHub where he was VP of Engineering. He is responsible for overseeing the strategic direction, development and deployment of the Frelii technology platform and AI, to ensure technology leadership and unique positioning for Frelii in their target industries.

“We now have a significant business development and strategic partnership presence led by our all-star executive team,” Jenkins continued. “Our consistent media coverage is reaching millions of influencers and we are also active at industry conferences in the US and Canada, including invitations to speak on the topics of artificial intelligence and precision medicine. While we will be a uniquely positioned company with progressive offerings across pharmaceutical, health and wellness, and precision medicine, we are particularly excited about our future opportunities in the CBD market. We believe many, if not most, suppliers of CBD products will eventually find our technology an integral part of their marketing, product selection and application processes.”

About Frelii Inc.

Frelii Inc. is a biotech company that uses whole human DNA gene sequencing (3.2 billion genetic pairs) and artificial intelligence (AI) to specifically assess 60 million genetic markers for each individual DNA kit we process. The results are aligned and leveraged against its AI, as a means of creating a very strong and powerful data platform for use by the Health & Wellness, Healthcare, Medical Cannabis and Pharmaceutical industries. Frelii’s technology generates accurate and profoundly valuable insight into an individual’s DNA. The company provides DNA Kit Packages and customized reporting for consumers, patients and healthcare providers to ensure the ideal treatment, drugs and dosing are a prime “fit” to the individual. For more information, please visit www.frelii.com. Frelii (OTCQB: FRLI) trades on the #OTCQB Venture Market for early stage and developing U.S. and international companies. Companies are current in their reporting and undergo an annual verification and management certification process. Investors can find Real-Time quotes and market information for the company on www.otcmarkets.com.

Follow Frelii online at:

Frelii Facebook Page https://www.facebook.com/livefrelii/
Frelii Twitter Feed @livefrelii
Frelii Instagram Page @livefrelii
Frelii LinkedIn Page linkedin.com/company/frelii/

Safe Harbor Statement:

This release contains certain “forward-looking statements” relating to the business of the Company. All statements, other than statements of historical fact included herein are “forward-looking statements” including statements regarding: the continued growth of the e-commerce segment and the ability of the Company to continue its expansion into that segment; the ability of the Company to attract customers and partners and generate revenues; the ability of the Company to successfully execute its business plan; the business strategy, plans, and objectives of the Company; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as “believes,” “expects” or similar expressions and involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this news release. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company’s periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume any duty to update these forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190522005827/en/